Gol Minoo Golshani
Biography
Gol Minoo Golshani, M.D., is an Assistant Clinical Professor, Step 3, in Hematology/Oncology at the University of California-Irvine. She received her medical degree from St. Georges University School of Medicine in 2014, followed by residency training in Internal Medicine at SUNY Stony Brook University and fellowship training in Hematology/Oncology at the same institution, completing her fellowship in 2020.
Golshani is board certified by the American Board of Internal Medicine in Internal Medicine, Medical Oncology, and Hematology. Prior to joining UC Irvine in 2024, she practiced as a hematologist/oncologist at The Oncology Institute of Hope and Innovation, Montefiore Medical Center Riverside Hospital, and Long Island Community Hospital. Her clinical practice focuses on the treatment of hematologic malignancies and solid tumors.
Golshani has contributed to research on immunotherapy in cancer treatment, including work on adverse events associated with pembrolizumab and advances in immunotherapy for colorectal cancer. She is a member of the American Society of Clinical Oncology and the American Society of Hematology.
Return to topEducation
- BSc in Biological Sciences, Rutgers University, 2008
- BA in Middle Eastern Studies, Rutgers University, 2008
- MD, St. Georges University School of Medicine, 2014
Areas of Expertise
- Clinical Oncology
- Pembrolizumab Fatal Adverse Events
- Colorectal Cancer Immunotherapy
- Anemia Management Quality Improvement
- Hematologic Malignancies Treatment
- Cancer Patient Safety Outcomes
- Immune Checkpoint Inhibitor Toxicity
Recent Publications
- Sher AF, Golshani GM, Wu S, “Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis” (opens in new tab), Cancer Invest, vol. 38, no. 2, pp. 130-138, 2020.
- Golshani GM, Zhang Y, “Advances in Immunotherapy for Colorectal Cancer: A Review”, Therapeutic Advances in Gastroenterology, 2020.
This profile was created with the help of AI.
Last updated on 3/12/2026.